Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewR162 is a glutamate dehydrogenase (GHD1) inhibitor (IC50 = 23 μM). Decreases fumarate and ROS levels, attenuates glutathione peroxidase levels and inhibits cell proliferation in cancer cell lines. Attenuates viability of a range of cancer cell lines.
M. Wt | 264.28 |
Formula | C17H12O3 |
Storage | Store at -20°C |
Purity | ≥98% (HPLC) |
CAS Number | 64302-87-0 |
PubChem ID | 4412951 |
InChI Key | IMUBGIOLZQTIGI-UHFFFAOYSA-N |
Smiles | OC1=C2C(C3=CC=CC=C3C(C2=CC=C1CC=C)=O)=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
Jin et al (2015) Glutamate dehydrogenase 1 signals through antioxidant glutathione peroxidase 1 to regulate redox homeostasis and tumor growth. Cancer Cell. 27 257 PMID: 25670081
Keywords: R162, R162 supplier, glutamate, dehydrogenase, inhibitor, inhibits, GDH1, Other, Dehydrogenases, 6054, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for R162.
There are currently no reviews for this product. Be the first to review R162 and earn rewards!
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
This product guide reviews some of the main areas in cancer metabolism research and lists around 150 products that can be used to investigate metabolic pathways in cancer including:
This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.